Shreel Parikh

Dr. Shreel Parikh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ZSZohaib Sherwani
Zohaib Sherwani
SPShreel Parikh
Shreel Parikh
NYNikhil Yegya-Raman
Nikhil Yegya-Raman
KMKelly McKenna
Kelly McKenna
MDMatthew Deek
Matthew Deek
LHLara Hathout
Lara Hathout
Historically, the role of radiation in gynecological metastatic disease involved palliation for pain or bleeding. Stereotactic Body Radiation Therapy (SBRT) has shown survival benefits in oligometastatic disease from varying primary histologies in recent randomized trials. However, gynecologic primary oligometastases have been underrepresented in these trials. Recent studies across gynecological malignancy types have similarly shown favorable outcomes and acceptable toxicities from treating recurrent or oligometastatic gynecologic cancer (ROMGC) patients with definitive radiation therapy. The largest body of literature reported on the use of SBRT in ovarian cancer, which was found to be an effective option, especially in the setting of chemo-resistant disease. Despite the encouraging outcomes using SBRT in oligometastatic gynecologic malignancies, SBRT remains underutilized given the lack of randomized studies studying ROMGC with long term follow-up. While waiting for future prospective trials to establish the role of SBRT as the standard of care in ROMGC patients, this review focuses on reporting the advantages and drawbacks of this technique and examines the current literature to help guide patient centered treatment decisions.

Verified
Journal Article
Open access
PDF file
SMSwati Mamidanna
Swati Mamidanna
MBMenal Bhandari
Menal Bhandari
CSCharvi Shah
Charvi Shah
LBLudvinna Bazile
Ludvinna Bazile
SGSukhdeep Gill
Sukhdeep Gill
RKRitesh Kumar
Ritesh Kumar
Small cell lung cancer (SCLC) is an aggressive malignancy with a high incidence of brain metastases. Prophylactic cranial irradiation (PCI) was developed to reduce central nervous system (CNS) relapses and has been shown to improve survival, particularly in limited-stage disease. The pivotal Auperin meta-analysis and subsequent studies confirmed its role in patients achieving a complete response to initial therapy. In extensive-stage SCLC, earlier trials demonstrated reduced brain metastases and modest survival gains, but more recent studies incorporating routine magnetic resonance imaging (MRI) surveillance failed to show overall survival benefits, supporting MRI monitoring with salvage therapy as an alternative. Neurocognitive toxicity remains the major limitation of PCI, especially in older adults. Common effects include memory impairment, cognitive changes, and a reduced quality of life. Advances such as hippocampal avoidance PCI and neuroprotective strategies like memantine have shown the ability to mitigate long-term decline. Modern radiotherapy techniques, including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT), enable the precise sparing of critical structures while maintaining intracranial control. The integration of immunotherapy has shifted treatment paradigms in SCLC. While checkpoint inhibitors have improved systemic outcomes, their impact on brain relapses and interactions with PCI remain uncertain. This review provides an overview of the evolution of PCI in SCLC, while emphasizing current challenges and future directions.

2 February 2024 in Brachytherapy
Verified
Journal Article
Closed access
SPShreel Parikh
Shreel Parikh
YZYingting Zhang
Yingting Zhang
ZSZohaib Sherwani
Zohaib Sherwani
RKRitesh Kumar
Ritesh Kumar
NONisha Ohri
Nisha Ohri
LHLara Hathout
Lara Hathout

30 December 2023 in Practical Radiation Oncology
Verified
Journal Article
Closed access
SPShreel Parikh
Shreel Parikh
NYNing Yue
Ning Yue
BCBruce Carmona
Bruce Carmona
JLJason Lambiase
Jason Lambiase
SKSung Kim
Sung Kim